Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
未来肿瘤学（ISSN 1479-6694）为癌症护理的新时代提供了一个论坛。该杂志重点关注最重要的进展，并强调其在临床环境中的相关性。此外，《未来肿瘤学》以简明扼要、一目了然的文章格式提供重要信息--这对于向时间日益紧迫的社区提供信息至关重要。该杂志对科学和临床问题以及我们在癌症护理新时代所面临的经济和政策问题采取前瞻性立场。该杂志包括文献意识，如放射治疗和免疫治疗的最新进展，简明的评论和分析，以及完整的综述文章，所有这些文章都提供了关键的发现，转化为临床背景。
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0736
Necitumumab for the treatment of advanced non-small-cell lung cancer.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0594
HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0809
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0317
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0668
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0324
Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0654
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0882
Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0480
Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0262
Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0348
Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0896
Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0564
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0130
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
来源期刊：Future oncologyDOI：10.2217/fon-2018-0948
FMO1 gene expression independently predicts favorable recurrence-free survival of classical papillary thyroid cancer.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0885
Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0659
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0388
Predicting lymph node metastasis in early gastric cancer patients: development and validation of a model.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0377
The evolution of value with filgrastim in oncology.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0762
Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0467
Ramucirumab and its use in the treatment of hepatocellular carcinoma.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0822
Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0527
Expression of YY1 in Wilms tumors with favorable histology is a risk factor for adverse outcomes.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0764
Clinicopathological parameters and survival of invasive epithelial ovarian cancer by histotype and disease stage.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0886
Signatures of gene expression, DNA methylation and microRNAs of hepatocellular carcinoma with vascular invasion.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0909
Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0298
The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0635
The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0258
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0934
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
来源期刊：Future oncologyDOI：10.2217/fon-2019-0490
Suspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case-control study.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0442
New advance in breast cancer pathology and imaging.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0017
mirRNA-365b promotes hepatocellular carcinoma cell migration and invasion by downregulating SGTB.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0676
Breast cancer with rare metastatic manifestation.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0263
Assessment of the response of hepatocellular carcinoma to interventional radiology treatments.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0747
Prognostic values of lymphocyte and eosinophil counts in resectable cervical squamous cell carcinoma.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0879
Real-world incidence and cost of pneumonitis post-chemoradiotherapy for stage III non-small-cell lung cancer.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0524
Clinical analysis of bone metastasis of gastric cancer: incidence, clinicopathological features and survival.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0039
Automated extraction of treatment patterns from social media posts: an exploratory analysis in renal cell carcinoma.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0406
Dedifferentiated liposarcoma: when eribulin can make the difference.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0598
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0140
Cigarette smoking promotes cancer-related transformation of oral epithelial cells through activation of Wnt and MAPK pathway.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0338
Servier in oncology: bringing innovation to patients.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0125
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0578
Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0127
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
来源期刊：Future oncologyDOI：10.2217/fon-2018-0826
Relationship of single nucleotide polymorphisms and haplotype interaction of mitochondrial unfolded protein response pathway genes with head and neck cancer.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0365
Nilotinib in the treatment of chronic myeloid leukemia.
来源期刊：Future oncologyDOI：10.2217/fon-2018-0468
Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice.
来源期刊：Future oncologyDOI：10.2217/fon-2019-0096
